OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: NeuroVision Imaging, Inc.

2 Projects | 2 Researchers | $2,740,209 Invested

2021

NeuroVision Imaging, Inc.

Leyla Anderson, MD, PhD, D(ABMLI)

Validation and commercialization of a novel blood-based, ultra-multiplex Laboratory Developed Test (LDT) for the prediction of cerebral amyloid status before clinical onset of dementia.

  • Funding Amount: $2,200,950
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Closed

2020

NeuroVision Imaging, Inc.

Blaine Roberts, PhD

Validation of blood based biomarkers for the detection of brain amyloid accumulation before clinical onset of dementia.

  • Funding Amount: $539,259
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Closed